(reported by the Company)
Proteomics International is a medical technology company specialising in providing sophisticated analytical services and developing new diagnostic tests for chronic diseases. The company’s core technology platform uses proteomics – the industrial-scale study of the structure and function of proteins. In 2015–16, PI grew its analytical services business in India, secured its first contracts in the Middle East, improved distribution channels in Japan and expanded into Central America. An ongoing partnership with InVentiv Health led to new market expansion opportunities in the US. Exports account for 40 per cent of PI’s total revenue.
Part of the PILL group.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):||PIQ|
|Year of Commencement:||2001|
QEII Medical Centre
WA Exporter of the Year 2016
|Current Period Rank:|
|WA Annual Rank 2016:||66|
Overall winner of WA Industry and Export Awards
Signed production contract with Monash Antibody Technologies Facility to produce the custom antibodies needed for a multiplex ELISA
Appointed Roger Moore as a Non-Executive Director
NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking
|Type of capital raise:|
|Investment Phone:||Investment phone:|